The role of donor-specific HLA alloantibodies in liver transplantation

American Journal of Transplantation

Volumn 14, Issue 4, 2014, Pages 779-787

  O'Leary, J G ^a   Demetris, A J ^b   Friedman, L S ^c   Gebel, H M ^d   Halloran, P F ^e   Kirk, A D ^d   Knechtle, S J ^d   McDiarmid, S V ^f   Shaked, A ^g   Terasaki, P I ^h   Tinckam, K J ⁱ   Tomlanovich, S J ^j   Wood, K J ^k   Woodle, E S ^l   Zachary, A A ^m   Klintmalm, G B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NEWTON WELLESLEY HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h TERASAKI FOUNDATION LABORATORY   (United States)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Antibody mediated rejection; donor specific HLA antibodies; graft outcomes; liver transplant; renal transplant; simultaneous liver kidney transplant

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; DONOR SPECIFIC HLA ALLOANTIBODY; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; AUTOIMMUNE HEPATITIS; CHOLESTASIS; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT REJECTION; HLA MATCHING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER; LIVER DISEASE; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MEDICAL EXPERT; PATHOPHYSIOLOGY; PLASMA CELL; PLASMA CELL HEPATITIS; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; SURGICAL RISK; T CELL MEDIATED REJECTION; DONOR; IMMUNOLOGY; LIVER DISEASES; PRACTICE GUIDELINE; PROGNOSIS; RESEARCH;

GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LIVER DISEASES; LIVER TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RESEARCH REPORT; TISSUE DONORS;

EID: 84897112141     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12667     Document Type: Conference Paper

References (38)

1. Patel R, Terasaki PI., Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
2. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
3. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
4. O'Leary JG, Kaneku H, Jennings LW, et al. Preformed Class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973-980.
5. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
6. Starzl TE, Demetris AJ, Todo S, et al. Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant 1989; 3: 37-45.
7. Takaya S, Duquesnoy R, Iwaki Y, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23: 396-399.
8. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
9. Zachary AA, Vega RM, Lucas DP, Leffell MS., HLA antibody detection and characterization by solid phase immunoassays: Methods and pitfalls. Methods Mol Biol 2012; 882: 289-308.
10. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
11. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132-2143.
12. Susal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: A Collaborative Transplant Study report. Transplantation 2011; 91: 883-887.
13. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013; 13: 1859-1870.
14. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
15. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
16. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal, subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293.
17. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance. Hepatology 1995; 21: 1345-1352.
18. O'Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20: 218-227.
19. Knechtle SJ, Kolbeck PC, Tsuchimoto S, Coundouriotis A, Sanfilippo F, Bollinger RR., Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. Transplantation 1987; 43: 8-12.
20. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
21. O'Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
22. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
23. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB., Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
24. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
25. O'Leary JG, Kaneku H, Jennings L, et al. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in HCV-infected patients. Liver Transpl 2014; in press.
26. Cousens LP, Najafian N, Mingozzi F, et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 2013; 33: S43-S49.
27. Iacob S, Cicinnati VR, Dechene A, et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int 2012; 32: 1253-1261.
28. Castillo-Rama M, Sebagh M, Sasatomi E, et al. " Plasma cell hepatitis" in liver allografts: Identification and characterization of an IgG4-rich cohort. Am J Transplant 2013; 13: 2966-2977.
29. Saidman SL, Duquesnoy RJ, Demetris AJ, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994; 2: 61-67.
30. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC Class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841-847.
31. Leca N, Warner P, Bakthavatsalam R, et al. Outcomes of simultaneous liver and kidney transplantation in relation to a high level of preformed donor-specific antibodies. Transplantation 2013; 96: 914-918.
32. Hanish SI, Samaniego M, Mezrich JD, et al. Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: A preliminary report. Transplantation 2010; 90: 52-60.
33. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51-59.
34. Demetris AJ, Nakamura K, Yagihashi A, et al. Clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671-681.
35. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: Can C4d stains help in monitoring ? Am J Transplant 2012; 12: 171-182.
36. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V., Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: Diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18: 641-658.
37. Franco A, Barnaba V, Natali P, Balsano C, Musca A, Balsano F., Expression of Class I and Class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988; 8: 449-454.
38. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526-2531.